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Objectives: The American College of Surgeons Oncology Group undertook a trial
to ascertain whether positron emission tomography with 18F-fluorodeoxyglucose
could detect lesions that would preclude pulmonary resection in a group of patients
with documented or suspected non–small cell lung cancer found to be surgical
candidates by routine staging procedures.
Methods: A total of 303 eligible patients registered from 22 institutions underwent
positron emission tomography after routine staging (computed tomography of chest
and upper abdomen, bone scintigraphy, and brain imaging) had deemed their tumors
resectable. Positive findings required confirmatory procedures.
Results: Positron emission tomography was significantly better than computed
tomography for the detection of N1 and N2/N3 disease (42% vs 13%, P  .0177,
and 58% vs 32%, P  .0041, respectively). The negative predictive value of
positron emission tomography for mediastinal node disease was 87%. Unsuspected
metastatic disease or second primary malignancy was identified in 18 of 287 patients
(6.3%). Distant metastatic disease indicated in 19 of 287 patients (6.6%) was
subsequently shown to be benign. By correctly identifying advanced disease (stages
IIIA, IIIB, and IV) or benign lesions, positron emission tomography potentially
avoided unnecessary thoracotomy in 1 of 5 patients.
Conclusions: In patients with suspected or proven non–small cell lung cancer
considered resectable by standard staging procedures, positron emission tomogra-
phy can prevent nontherapeutic thoracotomy in a significant number of cases. Use
of positron emission tomography for mediastinal staging should not be relied on as
a sole staging modality, and positive findings should be confirmed by mediastinos-
copy. Metastatic disease, especially a single site, identified by positron emission
tomography requires further confirmatory evaluation.
Accurate staging of non–small cell lung cancer (NSCLC) is essen-tial to the ability to offer a patient the most effective availabletreatment and the best estimate of prognosis. The most significantrecent advance in the staging of NSCLC has been the use ofpositron emission tomography (PET) with the glucose analog18F-fluoro-2-deoxy-D-glucose (FDG). FDG-PET provides infor-
mation regarding the functional activity of a malignant lesion rather than strictly
anatomic information as is provided by computed tomography (CT).
The use of PET for the evaluation of solitary pulmonary nodules is now well
established. Gould and colleagues1 performed a meta-analysis on 40 studies inclu-
sive of 1474 patients who had solitary lung nodules evaluated by PET. The overall
sensitivity for detection of malignancy was 96.8%, and the specificity was 77.8%.
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Evaluation of mediastinal nodal disease is crucial for
staging NSCLC. The accuracy of CT for predicting malig-
nant mediastinal lymphadenopathy is dismally low (sensi-
tivity 57% and specificity 82%), as reported in a meta-
analysis of 18 studies and 1045 patients by Toloza and
coworkers.2 This meta-analysis documented that PET has
improved sensitivity and specificity for the detection of
malignancy in the mediastinum (84% and 89%, respec-
tively). These results prompted the American College of
Chest Physicians in its recent lung cancer guidelines to
recommend FDG-PET for mediastinal staging.3
The use of PET for the detection of distant metastases
has been insufficiently studied, although reports have doc-
umented unexpected metastatic disease in 10% to 20% of
patients who are otherwise deemed candidates for sur-
gery.4,5 In addition, PET does not accurately detect metas-
tases to the brain because of the high uptake of FDG by
normal gray matter.
To validate the reported findings in single-institution
studies and to clarify the role of FDG-PET in the staging of
patients with potentially resectable NSCLC (stages I, II, and
selected IIIA), the American College of Surgeons Oncology
Group (ACOSOG) undertook the multi-institutional trial
Z0050. The primary objective was to ascertain whether
FDG-PET could detect lesions that would preclude pulmo-
nary resection in patients found to be surgical candidates
after standard imaging procedures.
Material and Methods
Regulatory Requirements
Investigators registering patients in the Z0050 trial were required
to be members in good standing of ACOSOG, and each clinical
site had active status with ACOSOG. The Z0050 protocol under-
went institutional review board approval at all clinical sites, and
subjects gave informed consent before participation in the study.
Before enrolling patients in the study, each participating institution
was required to submit its protocol for PET imaging along with
images from 3 consecutive PET studies for evaluation and ap-
proval by the ACOSOG PET Quality Assurance Committee.
Inclusion Criteria
Patients who had (1) a histologically or cytologically confirmed,
newly diagnosed, untreated, single-lesion NSCLC, (2) a single
lung lesion and a biopsy-proved unilateral mediastinal lymph node
metastasis, or (3) a clinical presentation strongly consistent with
primary bronchogenic carcinoma; who were medically fit; and
who were deemed surgical candidates (stage I, II, or IIIA disease)
after standard imaging procedures were eligible. The eligibility
criteria were designed to mimic standard clinical practice. Staging
procedures had to be performed within 60 days before registration.
Standard staging included CT of the chest and upper abdomen
(including the adrenals), bone scintigraphy, and contrast-enhanced
CT or magnetic resonance imaging (MRI) of the brain. Patients
with previous cancers were eligible if curative therapy had been
undertaken, there was no evidence of malignancy in the past 5
years, and there was low risk for recurrence. Patients were ex-
cluded if they had prior PET for evaluation of NSCLC, evidence
by standard staging of stage IIIB or IV disease, or uncontrolled
diabetes mellitus.
Clinical and Radiologic Assessments
Clinical assessment included an extended history and physical
examination. CT of the chest and upper abdomen (including the
adrenals) was performed with fourth-generation scanners capable
of high resolution, wide-dynamic range, and rapid screening. In-
travenous contrast agent was administered (unless contraindicated
or if the lesion was peripheral and there was no evidence of
adenopathy). Whole-body bone scintigraphy was performed by
standard methods. Scintigraphic abnormalities were further eval-
uated by appropriate radiologic examinations (radiographs, CT, or
MRI) or biopsy or both to exclude metastatic disease. A scinti-
graphic abnormality with a normal radiograph was considered
metastatic disease unless biopsied or otherwise explained by MRI
or clinical correlation. CT or MRI of the brain was performed
before and after contrast agent administration (unless use of con-
trast material was contraindicated).
Study Schema
Patients who were clinically staged with I, II, or IIIA disease after
standard staging procedures and who were surgical candidates
were then registered in the Z0050 trial. The study schema is shown
in Figure 1.
FDG-PET
Full-ring dedicated scanners with bismuth germanate or sodium
iodide (NaI) detectors and with manufacturer-quoted in-plane spa-
tial resolution of less than 6 mm were used. Integrated PET and CT
scanners were not used in this trial. The scanners underwent
quality control evaluation on each day imaging was performed.
Patients fasted for at least 4 hours before the PET study, but they
were well hydrated. The blood glucose concentration was deter-
mined immediately before FDG administration, and the study was
not performed if the blood glucose concentration was greater than
200 mg/dL. Intravenous fluids, intravenous furosemide, and a
Foley catheter to minimize urinary tract FDG activity were rec-
ommended, but optional, if filtered backprojection was used for
image reconstruction. Patients in whom a Foley catheter was not
placed voided before imaging. FDG was obtained from a commer-
cial supplier or was prepared and quality controlled by the routine
method in use at the individual sites in a manner consistent with
state and federal regulations. The radiochemical purity of the FDG
was required to be greater than 90%. With a dedicated bismuth
germanate PET system, the FDG dose was 0.14 to 0.21 mCi/kg,
with a minimum dose of 10 mCi. With an NaI PET system, a dose
of 0.07 mCi/kg was used. FDG was administered intravenously
with the patient in a quiet, darkened room, where the patient
remained resting comfortably until the time of imaging.
PET imaging of the body was performed first, beginning ap-
proximately 45 to 60 minutes after FDG injection. The region
imaged extended from the upper/mid-neck to the upper thigh. A
series of 5 or 6 overlapping transmission scans (of 2-3 minutes
duration) were obtained with a rotating 68Ge/68Ga rod source for
each emission scan. A segmentation algorithm was used for atten-
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uation correction. With dedicated NaI PET systems, attenuation
correction was performed with a 137Cs source in accordance with
the manufacturer’s recommendations. Then, 5 or 6 corresponding
emission images (each 5-15 minutes in duration depending on the
patient’s size) were performed. The PET images were recon-
structed both with and without attenuation correction by standard
vendor-provided reconstruction algorithms, using either filtered
back projection with a Hann filter (frequency cutoff 0.6 Nyquist
 0.3 cycles/pixel) or ordered-subset expectation maximization
with an appropriate filter. After body imaging, a 3-dimensional
(10-minute duration) or 2-dimensional (30-minute duration) emis-
sion PET study of the brain was performed. A calculated attenu-
ation correction was applied to brain-emission data. The PET
images of the brain were reconstructed by filtered back projection
with use of a Hann filter (frequency cutoff 0.4  Nyquist  0.2
cycles/pixel).
An experienced nuclear medicine physician from each partic-
ipating site interpreted the PET images. The emission scans were
reviewed in axial, coronal, and sagittal planes and as maximum
pixel intensity reprojection images, along with transmission im-
ages to facilitate anatomic localization of abnormal activity. The
images were initially interpreted without knowledge of the results
of previously obtained CT, other imaging studies, or surgical
staging procedures. The images were then reinterpreted with the
help of the CT and the other available conventional imaging
studies. The interpreter’s degree of suspicion for cancer at the
primary site, in locoregional nodes, and at distant metastatic sites
was recorded on a standard form with use of a 5-point ordinal
categoric scale with the following categories: 4  definitely ab-
normal, 3  probably abnormal, 2  indeterminate, 1  probably
normal, and 0  definitely normal. Locoregional nodes were
evaluated in relation to mediastinal blood-pool activity (grade 3
and 4 uptakes were slightly and substantially greater than blood-
pool activity, respectively). A score of 3 or 4 was considered
positive for final data analysis.
The protocol required that mediastinal abnormalities detected
by PET be histologically confirmed with mediastinoscopy, medi-
astinotomy, thoracoscopy, endoscopic ultrasonography with fine-
needle aspiration, or thoracotomy. PET-detected hepatic lesions
required biopsy or fine-needle aspiration for cytology to confirm
metastatic disease. Benign-appearing cysts or hemangiomas could
be confirmed by either MRI or ultrasonography. PET-positive
adrenal lesions required biopsy. Osseous abnormalities seen on
PET had to be evaluated by appropriate imaging studies (plain
Figure 1. Schema of the American College of Surgeons Oncology Group Z0050 Trial.
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radiographs, CT, MRI, or repeat bone scintigraphy) or biopsy or
both.
A lesion reported as a probable metastasis by PET or standard
imaging studies but not biopsied was considered a false-positive
result if the lesion(s) remained unchanged at 6-month follow-up. If
surgical resection was performed, all accessible bronchopulmo-
nary, hilar, and mediastinal lymph nodes were removed and la-
beled according to the American Thoracic Society lymph node
mapping system. Mediastinal lymph nodes for right-sided lesions
included 2R, 4R, 7 (8 and 9 if present), and 10R. For left-sided
lesions, nodal stations included 5, 6, 7 (8 and 9 if present), 10L,
and 4L, if accessible.
The conventional and PET imaging studies from the first 3
patients at each site and a 20% random sample of subsequent
patients were reviewed by 3 radiology and nuclear medicine in-
vestigators to document that these studies were performed accord-
ing to protocol specifications.
Follow-Up
Follow-up was not required if pulmonary resection was not per-
formed. If surgical resection occurred, follow-up of patient and
disease status was required at 6 months.
Statistical Analysis
The primary objective of the ACOSOG Z0050 trial was to ascer-
tain whether FDG-PET scanning could detect lesions that would
preclude pulmonary resection in patients deemed to be surgical
candidates by standard imaging procedures. The study was de-
signed to assess the utility of FDG-PET using data from a clinical
construct in which the standard staging procedures had to be
performed and interpreted before the use of PET. The design for
the primary objective was such that the main unit of measurement
was the proportion of patients with negative findings ascertained
by standard staging procedures who were subsequently found to
have surgical contraindication as a result of the FDG-PET findings.
This proportion is therefore a simple measure of the utility of
FDG-PET. A true proportion less than 5% was considered clini-
cally insignificant, and a true proportion more than 10% was
considered clinically significant. The study was designed to test the
null hypothesis that the data are consistent with FDG-PET contra-
indicating surgery in less than 5% of the patients against the
alternative hypothesis that the data are consistent with FDG-PET
contraindicating surgery in 10% or more of the patients. A 2-stage
accrual design was used to follow for early termination if there was
strong early evidence to support the null hypothesis.6
In this 2-stage design, if 5 or fewer patients of the first 120
accrued to the study had PET findings that contraindicated surgery,
the study would have been terminated. Otherwise, the study would
continue to a second stage to accrue a total of 235 patients. This
design has a type I error of 5% and a power of 90%.
Results
From January 2000 to December 2002, 445 patients were
registered in the Z0050 trial from 22 institutions (Appendix
1). Seventy patients were from a single institution using a
consent form that did not follow ACOSOG-mandated insti-
tutional review board guidelines. These patients were elim-
inated from the analysis when this regulatory problem was
discovered by an ACOSOG audit of the site. Of the remain-
ing 375 registered patients, 303 were deemed eligible, 12
were formally withdrawn by their site, and 60 were declared
ineligible at the time of internal ACOSOG review (16%).
Ineligible patients included those with nonresectable disease
documented by routine staging (14 patients), missing or
outdated staging procedures (15 patients), no adrenal as-
sessment on CT (9 patients), glucose level undocumented or
greater than 200 mg/dL (9 patients), regulatory violations (6
patients), and a variety of other reasons (7 patients). Of the
303 eligible patients, 302 were evaluable for PET staging of
T and N status (1 patient underwent esophageal biopsy after
PET and did not undergo operative staging as the result of
a diagnosis of invasive esophageal cancer). PET did not
include a separate set of brain images in an additional 15
patients as specified in the protocol, leaving 287 patients
who were ultimately evaluable for metastatic disease.
The mean age of eligible patients was 68.2 years (range
43.2-93.4 years); 163 were men and 140 were women. The
final histology is shown in Table 1. Of the benign lesions in
35 patients, 26 were confirmed pathologically and 9 were
presumed benign and followed.
The initial clinical stages of disease in the eligible pa-
tients (n  303) after standard staging procedures were the
following: IA in 125 patients (41.2%), IB in 106 patients
(35%), IIA in 5 patients (1.7%), IIB in 18 patients (6%), and
IIIA in 49 patients (16.2%).
PET correctly identified M1 disease (presumed to be M0
by standard imaging procedures) in 15 of 287 patients
(5.2%). The sites of metastases subsequently confirmed by
biopsy or radiographic study were bone in 5 patients, adre-
nal gland in 2 patients, extrathoracic lymph node in 2
patients, lung in 1 patient, liver in 1 patient, and colon in 1
patient. PET identified metastatic disease at multiple sites in
3 subjects, and therefore these patients did not undergo
surgical intervention. There were 3 additional patients who
had M1 disease discovered at thoracotomy that was missed
TABLE 1. Final histology of eligible patients
Histology No. patients %
Adenocarcinoma 122 40.3
Squamous cell carcinoma 78 25.7
Large cell carcinoma 12 4.0
Non–small cell carcinoma, undesignated 13 4.3
Bronchoalveolar carcinoma 11 3.6
Metastatic (non-lung) 7 2.3
Mixed adenocarcinoma/bronchoalveolar
carcinoma
3 1.0
Adenosquamous carcinoma 3 1.0
Small cell carcinoma 2 0.7
Other 17 5.6
Benign disease 35 11.6
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by both standard imaging and PET (2 patients with lung
disease and 1 patient with pleural disease). PET also iden-
tified 3 patients with second primaries: colon, lung, and
thyroid. In 19 of 287 evaluable patients (6.6%), possible M1
disease indicated by PET was subsequently excluded by
additional radiographic studies (13), by biopsies (4), or at
the time of surgical resection (2). The false-positive foci
were in brain (8), distant lymph nodes (2), bone (2), rectum,
thyroid, kidney, larynx, esophagus, liver, and contralateral
lung. There were 8 additional patients with M1 disease
indicated by PET; these findings were considered to be false
positive in the judgment of the surgeon, and no confirmatory
studies were performed. Three of the patients with pre-
sumed false-positive PET findings for M1 disease died
within 6 months, indicating that PET may have been cor-
rect. The sensitivity of PET for M1 disease was 83%, and
the specificity was 90%. The negative predictive value
(NPV) was 99%, and the positive predictive value (PPV)
was 36%. Of 62 eligible patients with positive findings on
history review or physical examinations, 4 had M1 disease
(of whom only 1 had symptoms consistent with the M1
site).
The ability to correctly classify nodal disease (N0, N1,
and N2/N3) confirmed pathologically by CT alone, PET
alone, and CT combined with PET is shown in Table 2. Of
the 303 eligible patients, 37 underwent a noncontrast chest
CT; 25 of these patients were evaluated for isolated periph-
eral nodules, and 12 patients did not receive contrast agent
because of allergy, patient refusal, or other reason. PET
correctly identified 128 of 168 patients (76%) with N0
disease, whereas CT correctly identified 147 of 168 patients
(88%) with N0 disease (P  .5). PET was superior to CT in
the identification of N1 disease (42% vs 13%; P  .0177).
PET correctly detected mediastinal lymph node disease
(N2/N3) in 58% of cases compared with 32% for CT (P 
.0041). The combined PET and CT readings did not signif-
icantly alter the findings of PET alone.
The ability of PET and CT to predict mediastinal nodal
disease is shown in Tables 3 and 4. For all eligible patients,
the sensitivity of PET for N2 and N3 disease was 61% and
the specificity was 84%. The NPV of PET was 87%, and the
PPV was 56%. The ability of CT to predict nodal disease is
shown in Table 4. For all eligible patients, the sensitivity of
CT to detect N2 and N3 disease was only 37%, but the
specificity was 91%. The NPV and PPV of CT were 81%
and 58%, respectively.
CT identified 48 evaluable patients with N2 disease
considered resectable by the participating surgeon. PET
correctly upstaged the disease in 5 of these patients to N3 or
M1. PET correctly identified unsuspected IIIA, IIIB, or M1
disease considered inoperable in another 38 patients. There-
fore in at least 43 evaluable patients, nontherapeutic thora-
cotomy could be avoided using information gained from
PET after standard staging procedures. When patients with
benign lesions correctly identified by PET and who under-
went thoracotomy are included (n  18), nontherapeutic
thoracotomy could potentially be avoided in 61 of 303
patients (20.1%). These results validate the 2-stage design
of this trial, such that the uniform minimum variance unbi-
ased estimate for the probability of FDG-PET contraindi-
cating surgery was 0.201 (95% Jennison-Turnbull confi-
dence interval 0.158-0.251).7,8
Discussion
From the patient’s viewpoint, staging of NSCLC is most
critical in assessing candidacy for potentially curative sur-
gical resection. The discovery of extrathoracic metastatic
TABLE 2. Correct classification of nodal status in patients
with primary lung cancer by imaging modality*
Confirmed
pathology
CT alone
(%)
PET alone
(%)
CT plus PET
(%)
P value
(PET vs CT)
N0 147/168 (88%) 128/168 (76%) 132/168 (89%) .5
N1 4/31 (13%) 13/31 (42%) 14/31 (45%) .0177
N2/N3 18/57 (32%) 33/57 (58%) 30/57 (53%) .004
CT, Computed tomography; PET, position emission tomography.
*Fraction of patients with nodal status confirmed pathologically and cor-
rectly staged by the imaging modality.
TABLE 3. Lymph node status comparing PET with final
stage (all eligible patients; n  302)*
By PET
Final stage (No. patients)
N0/N1 N2/N3 Total
N0/N1 191 29 220
N2/N3 36 46 82
Total 227 75 302
PPV, Positive predictive value; NPV, negative predictive value.
*Final stage equals nodal stage as determined radiographically or patho-
logically, including patients who did not have nodal status confirmed with
biopsy, mediastinoscopy, or surgical resection. For N2/N3 disease: sensi-
tivity  61%; specificity  84%; PPV  56%; NPV  87%.
TABLE 4. Lymph node status comparing CT with final stage
(all eligible patients; n  302)*
By CT
Final stage (No. patients)
N0/N1 N2/N3 Total
N0/N1 207 47 254
N2/N3 20 28 48
Total 227 75 302
*Final stage equals nodal stage as determined radiographically or patho-
logically, including patients who did not have nodal status confirmed with
biopsy, mediastinoscopy, or surgical resection. For N2/N3 disease: sensi-
tivity  37%; specificity  91%; PPV  58%; NPV  81%.
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disease is a contraindication to surgery except in very spe-
cialized circumstances (eg, solitary brain metastasis). Pa-
tients with involvement of mediastinal lymph nodes, either
ipsilateral (N2) or contralateral (N3), are usually not con-
sidered for primary surgical treatment. Some surgeons con-
sider selected patients with single-station N2 involvement
operable. The Z0050 protocol allowed inclusion of these
patients to mirror clinical practice. Those patients without
distant metastasis and metastatic lymph nodes (N0) or with
only intrapulmonary or hilar lymph node disease (N1) are
generally considered suitable to undergo surgical resection.
PET adds a new dimension to the anatomic staging tools
routinely used to evaluate NSCLC. Because of relatively
poor spatial resolution of PET, the functional information it
provides is considered complementary to the anatomic in-
formation provided by CT. This complementary use is es-
pecially important in the accurate assessment of the tumor
itself (T status) and the evaluation of intrapulmonary nodes
close to the mediastinum. Our study shows that although
neither CT nor PET is highly successful in identifying N1
disease, PET is significantly better.
For mediastinal lymph node staging, PET has been found
to be superior by meta-analysis in detecting and excluding
metastatic disease when compared with CT.9,10 For all
prospective studies comparing PET and CT in at least 50
patients, the overall accuracy of FDG-PET in the detection
of mediastinal lymph node involvement was 90% with a
sensitivity of 85% and a specificity of 92%.11 CT was
accurate in only 65% of cases with a sensitivity of 75% and
a specificity of 80%. In the present study, PET was signif-
icantly better than CT in the correct identification of N2 or
N3 disease, but the sensitivity of PET for mediastinal dis-
ease (61%) was considerably less than in previous reports.
The result, however, is very similar to the sensitivity in a
prospective series reported by Gonzalez-Stawinski and col-
leagues from Duke.12 The sensitivity of PET for mediastinal
staging in recent studies is documented in Table 5.12-16
The NPV of PET for N2 and N3 disease in this study was
87%. The controversy regarding the need for further inva-
sive mediastinal staging in light of a negative PET finding is
related to single institutional experience, surgeon threshold,
and published findings. Kerstine and coworkers15 reported
that if the PET finding was negative in N2 or N3 stations,
there was a 1% to 8% likelihood of mediastinal cancer. The
authors believed the findings justified the continued use of
mediastinoscopy. In the study by Vesselle and colleagues,16
PET underestimated the presence of N2 nodal disease in
6.8% of patients. Graeter and colleagues17 analyzed the
results of 82 patients with NSCLC with radiologically sus-
pected mediastinal lymph nodes and found the NPV of PET
to be 98.4%. They therefore concluded that mediastinos-
copy could be omitted in this situation. However, this study
is not comparable to most others, in which the findings of
PET were evaluated in patients with negative CT scans. The
Z0050 trial validates that mediastinoscopy must still be
considered the gold standard. Many reports substantiate that
PET can be very useful in guiding mediastinal biopsy,
particularly when PET demonstrates a lesion in a nodal
station not amenable to mediastinoscopy.
Discovery of distant metastatic disease precludes surgi-
cal resection. Routine staging includes bone scintigraphy,
CT or MRI of the brain, abdominal CT, and occasionally
ultrasonography. FDG-PET is an attractive modality for
finding distant metastases because the whole body can be
evaluated in 1 imaging session. However, FDG-PET has not
been useful for the detection of brain metastasis because the
lesions are often obscured by the high FDG uptake in
normal gray matter.18 Although bone scintigraphy is rea-
sonably sensitive, it is hampered by its low specificity
requiring additional studies. FDG-PET was found superior
to bone scintigraphy in 2 studies.19,20 PET may also identify
earlier disease, such as marrow metastases. Approximately
20% of patients with NSCLC present with adrenal masses,
but many are benign adrenal adenomas. The usefulness of
FDG-PET in the evaluation of an adrenal mass has been
reported, and 3 studies found a sensitivity of 100%.21-23
Studies evaluating the performance of FDG-PET for detect-
ing liver metastases from NSCLC have been limited. Iso-
lated liver metastasis is rare and usually identified by CT or
ultrasonography, but PET may be more specific. Thus,
FDG-PET may be the most appropriate modality in combi-
nation with CT or MRI of the brain to assess extrathoracic
disease.
FDG-PET has been reported to detect occult extratho-
racic metastases in 11% to 17% of patients with tumors
deemed resectable by conventional methods.4,14,24,25 In this
study of potentially resectable tumors as determined by
mandated complete staging procedures, the detection of
unsuspected metastases was much lower at 6.3%. However,
the study was not designed to assess the utility of PET as an
initial evaluation for metastatic disease, because patients
with metastases discovered by routine scans were not reg-
istered. PET identified 19 of 287 patients (6.6%) with find-
ings indicative of M1 lesions that were subsequently proven
not to be metastatic. Of importance is the fact that a signif-
TABLE 5. Mediastinal staging with PET
Author Year
No.
patients
Sensitivity
(%)
Specificity
(%)
Roberts et al13 2000 100 88 91
Gupta et al14 2001 77 87 91
Kerstine et al15 2002 237 82 82
Vesselle et al16 2002 118 81 96
Gonzalez-Stawinski et al12 2003 203 64 77
Z0050 2003 271 61 84
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icant number of patients with M1 disease identified by PET
could have been denied curative surgery. In 3 patients, new
primary cancers were discovered. In another 8 patients,
abnormal uptake in the brain was noted. Further assessment
is required when M1 disease is identified by PET, especially
if it is in a single site or in the brain.
The primary objective of this trial was to evaluate the
usefulness of adding PET for staging disease in patients
with documented NSCLC or believed to have bronchogenic
carcinoma and who had undergone complete routine staging
procedures. This trial therefore differs from most other
series in which incomplete staging was performed. The
ACOSOG Z0050 trial confirms the usefulness of PET in
this setting. Advanced, unresectable disease was found in 43
of 303 patients (14.2%). When the identification of benign
disease is also considered, approximately 1 in 5 patients
could avoid nontherapeutic thoracotomy (20.1%). This
study validates the findings of the PLUS trial5 in which
addition of PET to conventional workup prevented unnec-
essary surgery in 1 of 5 patients with suspected or proven
NSCLC.
The Z0050 study differs from the PLUS trial by requir-
ing radiographic staging in all patients before PET. The
conventional workup in the PET cohort of the PLUS trial
included bone scintigraphy in 27%, brain CT and MRI in
5%, and abdominal CT and ultrasonography in 46%. The
PLUS trial also included twice as many patients with locally
advanced (IIIA and IIIB) disease compared with the Z0050
trial.
Although PET is better than CT in identifying mediasti-
nal disease, a significant number of patients will still have
N2 or N3 disease when PET findings are negative. PET
positivity is dependent on tumor cell volume, tumor density,
and avidity for FDG. In many cases, lymph node positivity
corresponds to microscopic deposits of tumor cells. Inva-
sive mediastinal staging therefore is still recommended. A
high false-positive rate is found in geographic areas where
granulomatous or other inflammatory diseases (eg, his-
toplasmosis) are common. Positive PET findings in the
mediastinum should be confirmed, and PET may be very
useful to direct the location and type of invasive staging. In
patients with disease well staged by routine radiologic im-
aging, PET found only an additional 6.3% of patients with
M1 disease. In view of the low specificity of bone scintig-
raphy for osseous metastasis and CT scans for adrenal
metastasis, PET may be more useful than indicated by this
study. M1 disease identified by PET requires further eval-
uation because 6.6% of patients in the Z0050 trial poten-
tially would have been denied surgery if treatment decisions
were based on PET findings alone.
There were several limitations to this study. Patients with
suspected, but not biopsy-proven, NSCLC were eligible for
the study. A total of 11.6% of patients had benign disease.
However, the inclusion of such patients reflects clinical
practice. As noted, discrimination of N2 and N3 disease was
not always possible because of the clinical practice of
halting mediastinoscopy when biopsy at 1 level is positive.
Patients with stage IIIA disease were allowed in the study if
the surgeon considered the disease resectable after routine
staging. A final weakness was the lack of required follow-up
in patients not undergoing resection.
The usefulness of PET in the staging of lung cancer is
evolving. The Z0050 trial has shown that currently PET has
the ability to prevent nontherapeutic thoracotomy in a high
percentage of patients, even after thorough staging proce-
dures. The initial enthusiasm for PET as the sole staging
tool for mediastinal disease must clearly be tempered. The
ability of PET-CT fusion imaging to improve on the sensi-
tivity and specificity of PET alone has recently been report-
ed,26 but assessment of the role of this new approach awaits
further study.
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Paul Waters (New York, NY), David Jablons (San Francisco,
Calif), Jack B. Thigpen (Lakeland, Fla), and Robert Kennan (Pitts-
burgh, Pa).
Discussion
Dr Robert J. Cerfolio (Birmingham, Ala) Dr Reed, that was an
excellent presentation concerning a very important clinical topic.
Perhaps the most important message that can be gleaned from this
project is that multiple surgeons along with radiologists and pa-
thologists from many different institutions can construct and then
carry out a high-quality study in an attempt to answer an important
clinical question that we all have. It takes an incredible amount of
time, energy, and work from a whole lot of people, including
multiple institutional review boards, and I hope we all continue to
work in this manner. I want to first congratulate you on completing
and now presenting this trial.
Now, as general thoracic surgeons, we are always trying to
improve our patient selection for those afflicted with lung cancer.
There is no question that PET with FDG allows us to do this, but
unfortunately it is not as great as we all hoped. Although PET is
good, it “ain’t the great hope” that we all envisioned. It clearly
helps us to target areas to biopsy, but there are lots of false-
positives and negatives. Now, many hospitals claim to have a PET
when indeed they have a pseudo-PET, and I believe this is one of
the biggest problems facing PET scans today. Many patients come
to see us in our clinic and already have had a PET performed,
oftentimes at an unknown center, on unspecified cameras.
So my first question to you is, what tricks do you have that we
can use in our clinics that can help us determine what type of
machine was used to perform the PET scan and who read it, which
may be even more important. How can we help educate insurance
companies to pay for a repeat PET on a real dedicated PET with
the proper thickness camera when it is indicated?
The second problem facing PETs today is the SUVs. This
acronym, which stands for standardized uptake values, is really an
oxymoron more than an acronym. SUVs are clearly not standard-
ized. An SUV of 3.0 at my center, which may mean a nodule is
malignant, may be an SUV of 2.2 at your center, meaning it might
be benign. What steps are being done to help with this problem?
That brings us to PET for the mediastinal lymph nodes. In your
report you chose not to report the sensitivity, specificity, PPV,
NPV, or accuracy of FDG-PET for N1, N2, and N3 nodes sepa-
rately, as we and most others have reported. Moreover, you
grouped the N2s and N3s together. The results you reported are
lower than other reports. Can you explain why? Did you see many
false-positives from histoplasmosis and silicosis as we and others
have reported? False positivity in the lymph nodes is a real
problem with PET, and we believe a positive PET finding for a
mediastinal lymph node only means that a biopsy is indicated. Do
you agree? We have shown that PET seems to be more accurate in
some N2 stations than others. Did you evaluate the accuracy in
different lymph node stations? And although false-positives are
more common than false-negatives, it is the latter that I really
worry about. Can you discuss your false-negatives? Were they
from patients with microscopic disease? I know you mentioned
bronchoalveolar carcinoma in one of your slides, but I did not see
anything about carcinoid. Can you tell us about that?
My fourth question concerns PET for M1 disease—it seems to
be quite good. You have shown that PET is very accurate at
evaluating the liver and adrenal glands. However, what about the
brain (if scanned by PET) and the bone? We all agree that if a PET
indicates a brain lesion, an MRI of the brain is indicated, but do
you currently recommend an MRI for all asymptomatic patients?
Is PET often falsely negative for the brain? And how do you
handle a PET that indicates M1 disease in the hip, for example? Do
you obtain a bone scan or do you go right to an MRI, and if the
MRI is positive for the bone, is that study in and of itself good
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enough without tissue to deny a patient a pulmonary resection? We
have had several false-positive MRI scans of the bone.
Finally, you have shown that PET and CT are poor for N1
disease, and again your reported accuracy is lower for both than in
many other reported series. Can you explain why? And do you
have any experience with PET-CT fusion for N1 or N2 disease?
We have completed a prospective randomized trial that compared
PET with PET-CT fusion and found that PET-CT is superior for
detecting N1 disease. There are many ongoing trials evaluating the
use of chemotherapy for early lung cancer, and the presence of N1
disease may change our preoperative management. Therefore, this
issue may turn out to be clinically important. Would you recom-
mend to someone who is about to build a PET center to buy a
PET-CT fusion machine or just a PET?
We are indebted for all your hard work. This is an important
article and a great presentation, and I thank you and the association
for your time.
Dr Reed. I thank Dr Cerfolio for his remarks and thoughtful
questions. This is the first ACOSOG trial to be completed. We
have learned much, and clearly we still need to educate surgeons
about clinical trials. I hope that future trials will be better, and I am
sure they will.
Dr Cerfolio’s questions about PET scanners and the SUVs
recorded from different institutions are important points. I do not
have specific answers for him. In this trial the PET scanning
protocol was very detailed, and studies from each participating
institution were reviewed and had to be approved by the ACOSOG
PET Quality Assurance Committee. And you alluded to some-
thing, I think, that may be more important: A dedicated, consistent
radiologist with whom the surgeon interacts is probably more
important than the scanner.
One of the weaknesses of this study was our inability to
accurately separate N2 and N3 disease. When PET findings were
positive for multiple levels, the surgeon often performed a medi-
astinoscopy to verify positivity and stopped after one of the levels
was positive by frozen section. I think your point about N2 levels
is important. We did not look at the different N2 stations, but we
could go back and do that and should. I can tell you that in a little
over half of the cases, positivity at pathology was only for a single
level. We obviously, as you do, believe that a PET positive finding
on the scan should be verified pathologically.
The lower sensitivity of PET than previously reported for
mediastinal disease is really not surprising, and I think more and
more surgeons are seeing this. PET positivity is dependent on
tumor cell volume, tumor density, and avidity for FDG. In many
cases, lymph node positivity corresponds to microscopic deposits
of tumor cells in these lymph nodes.
One of the lessons we learned from this trial is that a single site
of PET positivity must be confirmed. PET is very sensitive for
bone metastases, as has been documented in the literature. I think
most of us would consider a positive MRI after a PET scan as a
confirmatory procedure. I will tell you that of the many false-
positive PET findings for M1 disease, 6 were actually in the brain.
As always, however, the onus is on us to prove that a patient’s
tumor is not resectable.
Dr Frank C. Detterbeck (Chapel Hill, NC). There is a dra-
matic difference between the incidence of picking up distant
metastatic disease after a negative clinical evaluation depending on
whether the patient has clinical stage I, II, or III disease. Old data
of head CT and bone scan showed that 5% of patients with clinical
stage I disease had positive findings. There are data for PET and
patients with clinical stage I disease showing a less than 10%
incidence of systemic metastases, whereas patients with stage III
disease have a 20% or 30% incidence.
Have you looked at your results by clinical stage? And a related
question is, what is the bottom line? Do you recommend PET for
all patients with lung cancer or for patients with clinical stage I, II,
or III disease? What is it?
Dr Reed. First of all, concerning your first question on clinical
stage, of those patients with IIIA disease clinically (eg, there were,
I believe, 42 of them), PET findings upstaged the disease in 12
cases. So indeed, as the stage goes up, PET will show you
increased positivity. What is the bottom line? I think Bob alluded
to the fact that we had all hoped PET would be the magic tool, the
single tool, and clearly it is not. I think most of us are now using
PET more for extrathoracic metastases, particularly bone, adrenal,
and liver. We all appreciate that PET is not useful for the brain. I
think most of us have gone back to using more mediastinoscopy
because PET has not been as sensitive in the mediastinum. So I
think at a lot of institutions now the protocol is to add the PET after
a chest CT to look for that extrathoracic metastases, and whether
you add the MRI or head CT may be very dependent on the clinical
examination. The NPV of 87%, everybody has their own thresh-
old, as you know. It depends on your institution and what the PET
findings are in your institution, your personal threshold, and other
articles in the literature.
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